{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T18:12:08Z","timestamp":1778695928351,"version":"3.51.4"},"reference-count":32,"publisher":"BMJ","license":[{"start":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T00:00:00Z","timestamp":1778630400000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"National Health and Medical Research Council, Australia","award":["NHMRC 2010-1012"],"award-info":[{"award-number":["NHMRC 2010-1012"]}]},{"name":"Royal Australian NZ College of Ophthalmologists Eye Foundation","award":["2007-2009"],"award-info":[{"award-number":["2007-2009"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Br J Ophthalmol"],"accepted":{"date-parts":[[2026,4,8]]},"abstract":"<jats:sec>\n                    <jats:title>Background\/Aims<\/jats:title>\n                    <jats:p>To identify predictors of continued discontinuation of vascular endothelial growth factor (VEGF) inhibitors for retinal vein occlusion (RVO) after it has been suspended.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Eyes with RVO were identified in the Fight Retinal Blindness! registry that suspended VEGF inhibitors for \u2265180 days when visual acuity (VA) was \u226535 letters, from 1 December 2011\u20132021. The primary outcome was not resuming therapy through 24 months which defined success.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Half (186\/362 (51%)) of the eligible 6-month suspensions successfully continued through 24 months. Successful cessation attempts began earlier (9 vs 14 months; p=0.001), after greater VA improvement (mean, +12.6\u2009vs +8.5 letters; p=0.01) following more injections in the first 6 months (median, 5 vs 4; p&lt;0.001) and more intensive treatment than unsuccessful attempts (176\/362 (49%)). At month 6 without treatment, the mean (95%\u2009CI) changes in VA and central subfield thickness (CST) were in successful attempts +1.8 letters (+0.4 to +3.1) and \u221220\u2009\u00b5m (\u221234 to \u22126); unsuccessful attempts +0.5 letters (\u22121.1 to 2.0) and \u22122\u2009\u00b5m (\u221222 to +18). When therapy resumed in unsuccessful attempts (median, 9.5 months), VA and CST had deteriorated by \u22123.5 letters (\u22125.6 to \u22121.4) and +38\u2009\u00b5m (+20 to +57) since suspension. These trends were more pronounced in eyes with central retinal vein occlusion.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Eyes with RVO that achieve good outcomes early, following more intensive VEGF inhibition and that improve further over 6 months without therapy are likely to achieve sustained, treatment-free quiescence through 24 months.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bjo-2025-328709","type":"journal-article","created":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T17:20:20Z","timestamp":1778692820000},"page":"bjo-2025-328709","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Suspending vascular endothelial growth factor inhibitors in eyes with retinal vein occlusion"],"prefix":"10.1136","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6261-4679","authenticated-orcid":false,"given":"Adrian Robert","family":"Hunt","sequence":"first","affiliation":[{"name":"Ophthalmology, Westmead Hospital, Westmead, New South Wales, Australia"},{"name":"Save Sight Institute, The University of Sydney Faculty of Medicine and Health, Sydney, New South Wales, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7944-6923","authenticated-orcid":false,"given":"Yohei","family":"Hashimoto","sequence":"additional","affiliation":[{"name":"Save Sight Institute, The University of Sydney Faculty of Medicine and Health, Sydney, New South Wales, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Louise","family":"O\u2019Toole","sequence":"additional","affiliation":[{"name":"Mater Private Hospital, Dublin, Leinster, Ireland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Theodorus Leonardus","family":"Ponsioen","sequence":"additional","affiliation":[{"name":"Ophthalmology, Isala, Zwolle, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nandor","family":"Jaross","sequence":"additional","affiliation":[{"name":"Australian Eye Specialists, Wyndham, New South Wales, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samantha","family":"Fraser-Bell","sequence":"additional","affiliation":[{"name":"Save Sight Institute, The University of Sydney Faculty of Medicine and Health, Sydney, New South Wales, Australia"},{"name":"Sydney Retina Clinic, Sydney, New South Wales, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pavol","family":"Kusenda","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Retinal Centre, Ocular Microsurgery Centre, Bratislava, Slovakia, Bratislava, Slovakia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Socorro","family":"Alforja","sequence":"additional","affiliation":[{"name":"Institute Cl\u00ednic of Ophthalmology (ICOF), Hospital Clinic, Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Barthelmes","sequence":"additional","affiliation":[{"name":"Ophthalmology, Zurich University Hospital Department of Ophthalmology, Z\u00fcrich, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8580-0274","authenticated-orcid":false,"given":"Mark C","family":"Gillies","sequence":"additional","affiliation":[{"name":"Save Sight Institute, The University of Sydney Faculty of Medicine and Health, Sydney, New South Wales, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2026,5,13]]},"reference":[{"key":"2026051310201522000_bjo-2025-328709v1.1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2012.09.026"},{"key":"2026051310201522000_bjo-2025-328709v1.2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2013.08.012"},{"key":"2026051310201522000_bjo-2025-328709v1.3","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2011.02.038"},{"key":"2026051310201522000_bjo-2025-328709v1.4","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2015.09.035"},{"key":"2026051310201522000_bjo-2025-328709v1.5","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2011.02.022"},{"key":"2026051310201522000_bjo-2025-328709v1.6","doi-asserted-by":"publisher","DOI":"10.1159\/000502041"},{"key":"2026051310201522000_bjo-2025-328709v1.7","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.ophtha.2019.09.029","article-title":"Retinal Vein Occlusions Preferred Practice Pattern\u00ae","volume":"127","author":"Flaxel","year":"2020","journal-title":"Ophthalmology"},{"key":"2026051310201522000_bjo-2025-328709v1.8","article-title":"Anti-vascular endothelial growth factor for macular oedema secondary to branch retinal vein occlusion","volume":"7","author":"Shalchi","year":"2020","journal-title":"Cochrane Database Syst Rev"},{"key":"2026051310201522000_bjo-2025-328709v1.9","first-page":"27","article-title":"Central retinal vein occlusion: a prospective histopathologic study of 29 eyes in 28 cases","volume":"1","author":"Green","year":"1981","journal-title":"Retina"},{"key":"2026051310201522000_bjo-2025-328709v1.10","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2009.01.015"},{"key":"2026051310201522000_bjo-2025-328709v1.11","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2010.04.019"},{"key":"2026051310201522000_bjo-2025-328709v1.12","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1097\/IAE.0b013e31821801f5","article-title":"Hemicentral retinal vein occlusion: natural history of visual outcome","volume":"32","author":"Hayreh","year":"2012","journal-title":"Retina"},{"key":"2026051310201522000_bjo-2025-328709v1.13","first-page":"265","article-title":"Branch retinal vein occlusion: clinical findings, natural history, and management","volume":"7","author":"Margolis","year":"2006","journal-title":"Compr Ophthalmol Update"},{"key":"2026051310201522000_bjo-2025-328709v1.14","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2010.01.058"},{"key":"2026051310201522000_bjo-2025-328709v1.15","doi-asserted-by":"crossref","first-page":"84","DOI":"10.3928\/23258160-20210201-05","article-title":"Patterns and Predictors of Successful Treatment Discontinuation in Retinal Vein Occlusions With Macular Edema in the Real World","volume":"52","author":"Lo","year":"2021","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"key":"2026051310201522000_bjo-2025-328709v1.16","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.oret.2022.12.011","article-title":"OCT Predictors of Treatment Discontinuation in Eyes with Retinal Vein Occlusion and Macular Edema","volume":"7","author":"Lent-Schochet","year":"2023","journal-title":"Ophthalmol Retina"},{"key":"2026051310201522000_bjo-2025-328709v1.17","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.oret.2022.11.001","article-title":"Central Retinal Vein Occlusion 36-Month Outcomes with Anti-VEGF: The Fight Retinal Blindness! Registry","volume":"7","author":"Hunt","year":"2023","journal-title":"Ophthalmol Retina"},{"key":"2026051310201522000_bjo-2025-328709v1.18","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1016\/j.oret.2024.04.014","article-title":"Three-Year Outcomes of VEGF Inhibitors in Naive Branch Retinal Vein Occlusion: Fight Retinal Blindness!","volume":"8","author":"Alforja","year":"2024","journal-title":"Ophthalmol Retina"},{"key":"2026051310201522000_bjo-2025-328709v1.19","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.ajo.2019.03.029","article-title":"Loss of Peak Vision in Retinal Vein Occlusion Patients Treated for Macular Edema","volume":"205","author":"Iftikhar","year":"2019","journal-title":"Am J Ophthalmol"},{"key":"2026051310201522000_bjo-2025-328709v1.20","doi-asserted-by":"publisher","DOI":"10.1136\/bjophthalmol-2021-319180"},{"key":"2026051310201522000_bjo-2025-328709v1.21","doi-asserted-by":"publisher","DOI":"10.1097\/IAE.0b013e318296b271"},{"key":"2026051310201522000_bjo-2025-328709v1.22","unstructured":"World Health Organization . World report on vision. Licence: CC BY-NC-SA 3.0 IGO. 2019."},{"key":"2026051310201522000_bjo-2025-328709v1.23","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2007.11.008"},{"key":"2026051310201522000_bjo-2025-328709v1.24","unstructured":"R Core Team . The R project for statistical computing. [cited R-4.1.3.pkg; R is a free software environment for statistical computing and graphics. It compiles and runs on a wide variety of UNIX platforms, Windows and MacOS.]. 2020. Available: https:\/\/cran.r-project.org"},{"key":"2026051310201522000_bjo-2025-328709v1.25","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1016\/j.ophtha.2016.01.011","article-title":"Individualized Ranibizumab Regimen Driven by Stabilization Criteria for Central Retinal Vein Occlusion: Twelve-Month Results of the CRYSTAL Study","volume":"123","author":"Larsen","year":"2016","journal-title":"Ophthalmology"},{"key":"2026051310201522000_bjo-2025-328709v1.26","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1016\/j.ophtha.2016.02.030","article-title":"Individualized Stabilization Criteria-Driven Ranibizumab versus Laser in Branch Retinal Vein Occlusion: Six-Month Results of BRIGHTER","volume":"123","author":"Tadayoni","year":"2016","journal-title":"Ophthalmology"},{"key":"2026051310201522000_bjo-2025-328709v1.27","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2010.02.021"},{"key":"2026051310201522000_bjo-2025-328709v1.28","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2010.02.022"},{"key":"2026051310201522000_bjo-2025-328709v1.29","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2014.08.031"},{"key":"2026051310201522000_bjo-2025-328709v1.30","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1016\/j.ophtha.2014.01.027","article-title":"Intravitreal aflibercept injection for macular edema due to central retinal vein occlusion: two-year results from the COPERNICUS study","volume":"121","author":"Heier","year":"2014","journal-title":"Ophthalmology"},{"key":"2026051310201522000_bjo-2025-328709v1.31","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1111\/ceo.14490","article-title":"Outliers of Treatment Frequency in Retinal Vein Occlusion: 24-Month Comparative Analysis of Fight Retinal Blindness! Practitioners","volume":"53","author":"Ponsioen","year":"2025","journal-title":"Clin Exp Ophthalmol"},{"key":"2026051310201522000_bjo-2025-328709v1.32","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2013.08.038"}],"container-title":["British Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bjo-2025-328709","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T17:20:26Z","timestamp":1778692826000},"score":1,"resource":{"primary":{"URL":"https:\/\/bjo.bmj.com\/lookup\/doi\/10.1136\/bjo-2025-328709"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,13]]},"references-count":32,"alternative-id":["10.1136\/bjo-2025-328709"],"URL":"https:\/\/doi.org\/10.1136\/bjo-2025-328709","relation":{},"ISSN":["0007-1161","1468-2079"],"issn-type":[{"value":"0007-1161","type":"print"},{"value":"1468-2079","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,13]]}}}